NCT02084056View on ClinicalTrials.gov

Bioequivalence of a FDC Tablet of Linagliptin/Metformin (2.5mg/1000mg) Extended Release in Healthy Subjects.

PHASE1CompletedINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

July 31, 2014

Study Completion Date

July 31, 2014

Conditions
Healthy
Interventions
DRUG

Linagliptin

Linagliptin

DRUG

Metformin

Metformin

DRUG

Linagliptin/Metformin FDC

Linagliptin/Metformin FDC

Trial Locations (1)

Unknown

1288.11.1 Boehringer Ingelheim Investigational Site, Biberach

Sponsors
All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

Boehringer Ingelheim

INDUSTRY